Determinants of the effect of extracorporeal carbon dioxide removal in the SUPERNOVA trial: implications for trial design.

Ewan C GoligherAlain CombesDaniel BrodieNiall D FergusonAntonio M PesentiV Marco RanieriArthur S Slutskynull null

Published in: Intensive care medicine (2019)

The lung-protective benefits of ECCO2R increase with higher alveolar dead space fraction, lower respiratory system compliance, and higher device performance. ADF and Crs, rather than severity of hypoxemia, should be the primary factors determining whether to enroll patients in clinical trials of ECCO2R.

Keyphrases

clinical trial
carbon dioxide
phase ii
end stage renal disease
phase iii
study protocol
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
open label
randomized controlled trial
patient reported outcomes
patient reported